Year-end Sale % OFF 
Abstract
Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors.
Highlights
EXPRESSION OF CONCERN- In Figure 3, similarities were noted between the p-MAPK44/42 and pMEK blots for HCT116 cells
After publication of this article [1], the following concerns were raised about results reported in Figures 1, 3, 5, and 6:
- In Figure 3, similarities were noted between the p-MAPK44/42 and pMEK blots for HCT116 cells
Summary
- In Figure 3, similarities were noted between the p-MAPK44/42 and pMEK blots for HCT116 cells. - In Figure 3, similarities were noted between the p445-BRAF and pMEK blots for CALU-3 cells. The authors replicated the experiments for which concerns were raised using the same methods and conditions as in the original study [1]. The PLOS ONE Editors issue this Expression of Concern to notify readers of the issues raised for the published figures and the unavailability of original data for this study
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
